Diabetes Mellitus Clinical Trial
— IMPACTOfficial title:
Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study
| Verified date | March 2021 |
| Source | Stanford University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The Initiate and Maintain Physical Activity in Clinics (IMPACT) study will determine the optimal and feasible level of frequency of structured contact needed in a clinical setting for adult patients with Type 2 Diabetes Mellitus to initiate and maintain physical activity recommendations long-term.
| Status | Completed |
| Enrollment | 354 |
| Est. completion date | January 2020 |
| Est. primary completion date | January 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Recent hemoglobin A1c result between 6.5 and 13.0% - Diagnosed with Type 2 Diabetes Mellitus - Able and willing to enroll and meet the requirements of the study Exclusion Criteria: - Inability to speak, read or understand English - Long-term current use or dependency on insulin - Systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg - Resting heart rate > 120 bpm - History of or present heart or cardiovascular conditions - History of or present respiratory disease - History of or present spinal cord injury - History of stroke or Transient Ischemic Attack (TIA) - History of cancer diagnosis in the past 5 years or present cancer diagnosis - Medical, psychiatric, behavioral limitations that may interfere with study participation - Participating in other clinical trials that may interfere with study procedures and outcomes - Currently pregnant or plans to become pregnant within three years |
| Country | Name | City | State |
|---|---|---|---|
| United States | Stanford University | Palo Alto | California |
| Lead Sponsor | Collaborator |
|---|---|
| Stanford University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Changes in Hemoglobin A1c Level Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Primary | Changes in Maximal Oxygen Consumption Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Primary | Changes in Self-Reported Physical Activity Level Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Body Weight Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Body Mass Index Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Waist Circumference Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Blood Pressure Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Heart Rate Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Dietary Intake Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Self-Reported Quality of Life Across Study Visits | Baseline, 3-, 6-, 18-, 24-, 30-month follow-up | ||
| Secondary | Changes in Exercise Perception Across Study Visits | Baseline, 6-, 30-month follow-up | ||
| Secondary | Changes in Patient Satisfaction During Intervention Period | 3-, 6-month follow-up |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |